Results 81 to 90 of about 235,727 (237)

Simvastatin Improves Cardiac Function through Notch 1 Activation in BALB/c Mice with Chronic Chagas Cardiomyopathy

Antimicrobial Agents and Chemotherapy, 2020
Chagas disease, caused by the protozoan Trypanosoma cruzi, endemic in Latin America but distributed worldwide because of migration. Without appropriate treatment, the disease progresses from an acute asymptomatic phase to a chronic, progressive ...
Daniela Guzmán-Rivera, Ana Liempi, Fabiola González-Herrera, Sebastián Fuentes-Retamal, Ileana Carrillo, Patricio Abarca, C. Castillo, U. Kemmerling, B. Pesce, J. Maya   +9 more
semanticscholar   +1 more source

Lycopene's Role in Mitigating Obesity‐Induced Cardiac Remodeling: Insights Into Inflammatory and MMP‐2 Pathways

Molecular Nutrition &Food Research, Volume 70, Issue 2, 29 January 2026.
A. Consumption of a highsugar‐fat diet causes excess nutrients, hypertrophy and hyperplasia of adipocytes, causing obesity. Obesity leads to increased inflammatory levels in the heart, which stimulates greater activation of Metalloproteinase‐2 (MMP‐2), which has collagenolytic activity, degrading the collagen network in the heart, ultimately causing ...
Carol Cristina Vagula de Almeida de Silva, Artur Junio Togneri Ferron, Fabiane Valentini Francisqueti‐Ferron, Alexandre Ribeiro da Silva, Silmeia Garcia Zanati Bazan, Jéssica Leite Garcia, Dijon Henrique Salomé de Campos, Mariane Róvero Costa, Daniele Dantas, Heloysa Amaral da Silva, Janaina Paixão das Chagas Silva, Giselle Pinto Faria de Lopes, Bertha Furlan Polegato, Camila Renata Correa, Fernando Moreto, Ana Lucia Anjos Ferreira   +15 more
wiley   +1 more source

Deriving a parsimonious cardiac endpoint for use in epidemiological studies of Chagas disease: results from the Retrovirus Epidemiology Donor Study-II (REDS-II) cohort

Revista do Instituto de Medicina Tropical de São Paulo, 2021
Chagas cardiomyopathy (ChCM) is a severe consequence of Trypanosoma cruzi infection and has a range of electrocardiographic (ECG) and echocardiographic (ECHO) manifestations. There is a need for a standard and parsimonious research cardiac end point that
Lewis F. Buss, Taniela Marli Bes, Alexandre Pereira, Larissa Natany, Claudia Di Lorenzo Oliveira, Antonio Luiz P Ribeiro, Ester Cerdeira Sabino   +6 more
doaj   +1 more source

Cardiomyopathy protection in Chagas Disease [PDF]

World Journal of Cardiovascular Diseases, 2013
There is some published evidence suggesting micro vascular endothelial dysfunction and dysautonomia involvement in Chagas disease in association with cardiomyocyte changes favoring disease progression. The combined treatment between angiotensin converting enzyme (ACE) inhibitor drugs; Simvastatin, muscarinic antibody immunoadsorbent together with ...
Mitelman, Jorge E., Gimenez, Luisa
openaire   +2 more sources

Harnessing controlled human infection models to accelerate vaccine development for neglected tropical diseases: Lessons from leishmaniasis

European Journal of Clinical Investigation, Volume 56, Issue 1, January 2026.
Controlled Human Infection Models (CHIMs) offer a powerful approach to accelerate vaccine development for neglected tropical diseases (NTDs). This review highlights scientific and translational advances enabled by CHIMs, with a focus on a novel Leishmania major model.
Vivak Parkash
wiley   +1 more source

Ex vivo T-lymphocyte chemokine receptor phenotypes in patients with chronic Chagas disease

Revista da Sociedade Brasileira de Medicina Tropical
INTRODUCTION: Elucidating the molecules involved in the inflammatory process of chronic Chagas disease may allow identification of treatment targets.
Matheus Barbosa de Miranda, Adriene Siqueira de Melo, Mariana Silva Almeida, Silvia Martins Marinho, Wilson Oliveira Junior, Yara de Miranda Gomes   +5 more
doaj   +1 more source

Chagas disease cardiomyopathy: current concepts of an old disease Cardiomiopatia chagásica: conceitos atuais de doença antiga

Revista do Instituto de Medicina Tropical de São Paulo, 2008
Chagas disease continues to be a significant public health problem, as ca. 10 million people are still infected with T. cruzi in Latin America. Decades after primary infection, 30% of individuals can develop a form of chronic inflammatory cardiomyopathy ...
Angelina M.B. Bilate, Edecio Cunha-Neto
doaj   +1 more source

Long-Term Prognostic Value of Myocardial Fibrosis in Patients With Chagas Cardiomyopathy.

Journal of the American College of Cardiology, 2018
BACKGROUND Myocardial fibrosis (MF) according to cardiac magnetic resonance (CMR) is a frequent finding in Chagas cardiomyopathy and has been associated with risk factors of poor outcome.
Tiago Senra, B. Ianni, A. C. Costa, C. Mady, Martino Martinelli-Filho, R. Kalil‐Filho, C. Rochitte   +6 more
semanticscholar   +1 more source

Sex in Immune Cells and Parasitic Diseases — A Complex Relationship

Immunological Reviews, Volume 337, Issue 1, January 2026.
ABSTRACT Epidemiological studies consistently show that many parasitic diseases affect males more frequently than females. These disparities are multifactorial, arising partly from gender‐specific behaviors that influence exposure risk and health‐seeking practices, especially in low‐ and middle‐income countries. Increasing evidence also highlights that
Barbara Honecker, Charlotte Sophie Hansen, Hanna Lotter   +2 more
wiley   +1 more source

The P2X7 Receptor and Its Relation to Neglected Tropical Diseases: Focusing on Chagas Disease

Journal of Tropical Medicine, Volume 2026, Issue 1, 2026.
Chagas disease, caused by Trypanosoma cruzi, is a neglected tropical disease (NTD) that can lead to severe cardiac complications, including chronic Chagas cardiomyopathy. While NTDs are caused by a variety of pathogens—such as protozoa, bacteria, viruses, and helminths, Chagas disease remains underexplored, particularly regarding host immune responses.
Caroline de Souza Ferreira Pereira, Robson Xavier Faria, Wei Wang   +2 more
wiley   +1 more source